| CAT # | Magaca Alaabta | Sharaxaada |
| CPD100587 | Phlorizin | Phlorizin, oo sidoo kale loo yaqaan phloridzin, waa glucoside of phloretin, dihydrochalcone, qoys ka mid ah flavonoids-ka bicyclic, taas oo iyaduna ah koox-hoosaad ka tirsan dariiqa isku-dhafka phenylpropanoid ee kala duwan ee dhirta. Phlorizin waa xakameynta tartanka SGLT1 iyo SGLT2 sababtoo ah waxay la tartameysaa D-glucose si loogu xiro side; tani waxay yaraynaysaa socodka gulukooska kelyaha, iyadoo hoos u dhigaysa cadadka gulukooska ee dhiiga. Phlorizin waxaa loo bartay inay tahay daawaynta dawooyinka suurtagalka ah ee nooca 2-aad ee sonkorowga, laakiin tan iyo markaas waxaa beddelay analogs-ka-doorasho iyo rajo-gelin badan, sida canagliflozin iyo dapagliflozin. |
| CPD0045 | Ipragliflozin | Ipragliflozin, oo sidoo kale loo yaqaan ASP1941, waa xakameyn awood leh oo door ah SGLT2 si loogu daaweeyo nooca 2aad ee sonkorowga. Daaweynta Ipragliflozin waxay hagaajisay xakamaynta glycemic marka lagu daro daaweynta metformin waxaana laga yaabaa inay la xiriirto miisaanka oo yaraada iyo hoos u dhigista cadaadiska dhiigga marka loo eego placebo. Ipragliflozin ma wanaajiso hyperglycemia oo kaliya laakiin sidoo kale sonkorowga/ buurnaanta la xiriirta cilladaha dheef-shiid kiimikaad ee nooca 2 ee jiirka macaanka. Waxaa loo oggolaaday in lagu isticmaalo Japan 2014 |
| CPD100585 | Tofogliflozin | Tofogliflozin, oo sidoo kale loo yaqaan CSG 452, waa mid awood leh oo xulashada SGLT2 inhibitor ah oo hoos yimaada horumarinta daaweynta sonkorowga mellitus. Tofogliflozin waxay hagaajisaa xakamaynta glycemic waxayna hoos u dhigtaa miisaanka jidhka bukaanada qaba nooca 2 ee sonkorowga mellitus. Tofogliflozin qiyaasta ku tiirsanaanta la xakameeyey gulukooska gelitaanka unugyada tubular. Soo-gaadhista gulukooska sare (30?mM) ee 4 iyo 24?h waxay si weyn u kordhisay jiilka walbahaarka oksaydhka ee unugyada tubular, kuwaas oo lagu xakameeyay daaweynta tofogliflozin ama antioxidant N-acetylcysteine (NAC). |
| CPD100583 | Empagliflozin | Empagliflozin, oo sidoo kale loo yaqaan BI10773 (magaca ganacsiga Jardiance), waa daawada loo oggolaaday daaweynta nooca 2 ee sonkorowga ee dadka waaweyn 2014. Waxaa soo saaray Boehringer Ingelheim iyo Eli Lilly iyo Company. Empagliflozin waa horjooge soodhiyam gulukoos co-transporter-2 (SGLT-2), wuxuuna sababaa in sonkorta dhiiga ku jirta ay kelyuhu nuugto oo ay ka takhalusto kaadida. Empagliflozin waa horjooge soodhiyam gulukoos co-transporter-2 (SGLT-2), kaas oo si gaar ah looga helo tuubooyinka u dhow ee qaybaha nephronic ee kelyaha. SGLT-2 ayaa qiyaastii 90 boqolkiiba gulukoosta dib ugu soo laabta dhiigga. |
| CPD100582 | Canagliflozin | Canagliflozin (INN, magaca ganacsiga Invokana) waa daawo loogu talagalay daawaynta nooca 2aad ee sonkorowga. Waxaa soo saaray Mitsubishi Tanabe Pharma waxaana lagu suuq geeyaa shatiga Janssen, qayb ka mid ah Johnson & Johnson. Canagliflozin waa horjooge ka mid ah nooca 2-aad ee borotiinka-glucose-gulucose-ka ee borotiinka (SGLT2), kaas oo mas'uul ka ah ugu yaraan 90% dib u nuugista gulukooska ee kelyaha. Xiritaanka gaadiidkan waxay sababtaa in gulukoosta dhiigga lagu tirtiro kaadida. Bishii Maarso 2013, canagliflozin waxay noqotay horjooge SGLT2 ee ugu horreeyay ee laga oggolaado Mareykanka |
| CPD0003 | Dapagliflozin | Dapagliflozin, oo sidoo kale loo yaqaan BMS-512148, waa daawo loo isticmaalo daaweynta nooca 2 ee sonkorowga oo ay ansixisay 2012 FDA. Dapagliflozin waxay joojisaa nooca 2-aad ee borotiinnada gaadiidka sodium-glucose (SGLT2) kuwaas oo mas'uul ka ah ugu yaraan 90% gulukooska dib-u-noqoshada kelyaha. Xannibaadda habkan gaadiidka qaada waxay sababtaa in gulukoosta dhiigga lagu tirtiro kaadida. Tijaabooyin caafimaad, dapagliflozin waxay hoos u dhigtay HbA1c 0.6 iyo dhibcaha placebo markii lagu daro metformin |
